Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armatinib With or Without SBRT for First-line Treatment of EGFR-mutated NSCLC Brain Metastases
NCT05800223Phase 3Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University Shanghai Cancer Center. Started Jan 2023; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05800223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800223.